In Vitro Susceptibility of Various Genotypic Strains of Toxoplasma gondii to Pyrimethamine, Sulfadiazine, and Atovaquone

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-01-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.01203-07PMID 18212105PMCID PMC2292506
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention and treatment of congenital toxoplasmosis

  2007cited by this paper
• ROP18 Is a Rhoptry Kinase Controlling the Intracellular Proliferation of Toxoplasma gondii

  2007cited by this paper
• Comparison between Two Amplification Sets for Molecular Diagnosis of Toxoplasmosis by Real-Time PCR

  2006cited by this paper
• The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999–2002

  2006cited by this paper
• Reactivation of Toxoplasma Retinochoroiditis Under Atovaquone Therapy in an Immunocompetent Patient

  2006cited by this paper
• Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae.

  2006cited by this paper
• Genetic Divergence of Toxoplasma gondii Strains Associated with Ocular Toxoplasmosis, Brazil

  2006cited by this paper
• Genotyping of Toxoplasma gondii Strains from Immunocompromised Patients Reveals High Prevalence of Type I Strains

  2005cited by this paper
• Multiplex PCR for Typing Strains of Toxoplasma gondii

  2005cited by this paper
• Toxoplasma gondii is capable of exogenous folate transport. A likely expansion of the BT1 family of transmembrane proteins.

  2005cited by this paper
• Population Pharmacokinetics of Pyrimethamine and Sulfadoxine in Children Treated for Congenital Toxoplasmosis

  2004cited by this paper
• Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.

  2004cited by this paper
• Fitness of Toxoplasma gondii is not related to DHFR single-nucleotide polymorphism during congenital toxoplasmosis.

  2004cited by this paper
• Toxoplasmosis

  2004cited by this paper
• Randomized Phase II Trial of Atovaquone with Pyrimethamine or Sulfadiazine for Treatment of Toxoplasmic Encephalitis in Patients with Acquired Immunodeficiency Syndrome: ACTG 237/ANRS 039 Study

  2002cited by this paper
• Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.

  2002cited by this paper
• Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings.

  2002influential reference
• The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis.

  2002influential reference
• Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia.

  2001cited by this paper
• In Vitro Generation of Novel Pyrimethamine Resistance Mutations in the Toxoplasma gondiiDihydrofolate Reductase

  2001influential reference
• Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia

  2001cited by this paper
• Defining the cell cycle for the tachyzoite stage of Toxoplasma gondii.

  2001influential reference
• Unusual abundance of atypical strains associated with human ocular toxoplasmosis.

  2001cited by this paper
• Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS.

  2001cited by this paper
• Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance.

  2000influential reference
• Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.

  2000cited by this paper
• A Biochemical and Genetic Model for Parasite Resistance to Antifolates TOXOPLASMA GONDII PROVIDES INSIGHTS INTO PYRIMETHAMINE AND CYCLOGUANIL RESISTANCE IN PLASMODIUM FALCIPARUM*

  1998influential reference
• A Biochemical and Genetic Model for Parasite Resistance to Antifolates

  1998cited by this paper
• Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group.

  1997cited by this paper
• Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro

  1997cited by this paper
• Atovaquone as long‐term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance

  1996cited by this paper
• Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii

  1996cited by this paper
• Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii.

  1995cited by this paper
• Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease.

  1995influential reference
• Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis.

  1995cited by this paper
• Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria.

  1993cited by this paper
• Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate.

  1993cited by this paper
• In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii

  1993cited by this paper
• Toxoplasmic encephalitis in AIDS.

  1992cited by this paper
• Toxoplasma gondii: characterization of a mutant resistant to sulfonamides.

  1992cited by this paper
• Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group

  1992cited by this paper
• In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii

  1992cited by this paper
• Treatment of Toxoplasmic Encephalitis in Patients with AIDS

  1992cited by this paper
• Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

  1991cited by this paper
• In vitro effects of folate inhibitors on Toxoplasma gondii

  1989cited by this paper
• Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.

  1989cited by this paper
• Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture

  1988cited by this paper
• In vitro assessment of antimicrobial agents against Toxoplasma gondii.

  1988cited by this paper
• Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.

  1987cited by this paper
• Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1)

  1980influential reference
• Relative resistance of slow-growing strains of Toxoplasma gondii to pyrimethamine (daraprim).

  1959cited by this paper
• The development of a pyrimethamine-resistant line of Toxoplasma under in vitro conditions.

  1958cited by this paper

• Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoites

  2026cites this paper
• Evaluation of anti-Toxoplasma effects of lipid nanoparticles carrying tea tree oil on Toxoplasma gondii tachyzoites in Vero cells

  2025cites this paper
• In vitro and in vivo activity of quisinostat against Toxoplasma gondii

  2025cites this paper
• Assessing the Therapeutic Potential of Silicon Dioxide Nanoparticles in Acute and Chronic Toxoplasmosis in BALB/c mice.

  2025cites this paper
• BthTX-II, an Asp49 PLA2 from Bothrops jararacussu, Impairs Toxoplasma gondii Infection: In Vitro and Ex Vivo Approaches

  2025cites this paper
• MjTX-II, a Lys49-PLA2 from Bothrops moojeni snake venom, restricts Toxoplasma gondii infection via ROS and VEGF regulation.

  2025cites this paper
• Anti-Toxoplasma gondii studies of the venom peptide XYP4 from the Lycosa coelestis.

  2025cites this paper
• Novel drug candidates targeting Toxoplasma gondii in maternal–fetal interface models

  2025cites this paper
• Insights into the Role of Proteolytic and Adhesive Domains of Snake Venom Metalloproteinases from Bothrops spp. in the Control of Toxoplasma gondii Infection

  2025cites this paper
• In Vitro Evaluation of Anti-Parasitic Activities of Quinolone-Coumarin Hybrids Derived from Fluoroquinolones and Novobiocin Against Toxoplasma gondii

  2024cites this paper
• An alternative method to establish an early acute ocular toxoplasmosis model for experimental tests

  2024cites this paper
• In Vitro Anti-Toxoplasma Activity of Extracts Obtained from Tabebuia rosea and Tabebuia chrysantha: The Role of β-Amyrin

  2024cites this paper
• Anti‐Toxoplasma gondii activity of rose hip oil–solid lipid nanoparticles

  2024cites this paper
• Antiparasitic Effects of Niosomal Formulations of Curcumin and Silymarin Against Toxoplasma gondii In Vitro

  2024cites this paper
• Animal venoms: a novel source of anti-Toxoplasma gondii drug candidates

  2023cites this paper
• In vitro and in vivo susceptibility to sulfadiazine and pyrimethamine of Toxoplasma gondii strains isolated from Brazilian free wild birds

  2023cites this paper
• Anti-Toxoplasma gondii Effects of Lipopeptide Derivatives of Lycosin-I

  2023cites this paper
• Dimedone nanoparticle as a promising approach against toxoplasmosis: In vitro and in vivo evaluation.

  2023cites this paper
• Rottlerin impairs early and late steps of Toxoplasma gondii infection in human trophoblast cells and villous explants.

  2023cites this paper
• Surfactant vesicles for enhanced antitoxoplasmic effect of norfloxacin: in vitro and in vivo evaluations.

  2023cites this paper
• A Metabolomic and Transcriptomic Study Revealed the Mechanisms of Lumefantrine Inhibition of Toxoplasma gondii

  2023cites this paper
• Role of Host Small GTPases in Apicomplexan Parasite Infection

  2022cites this paper
• Identification of potent inhibitors against chorismate synthase of Toxoplasma gondii using molecular dynamics simulations.

  2022cites this paper
• Effects of Ovine Monocyte-Derived Macrophage Infection by Recently Isolated Toxoplasma gondii Strains Showing Different Phenotypic Traits

  2022cites this paper
• Toxoplasmosis: Current and Emerging Parasite Druggable Targets

  2021cites this paper
• Boromycin Has Potent Anti-Toxoplasma and Anti-Cryptosporidium Activity

  2021cites this paper
• Acridones Are Highly Potent Inhibitors of Toxoplasma gondii Tachyzoites.

  2021cites this paper
• Oxidative Stress as a Possible Target in the Treatment of Toxoplasmosis: Perspectives and Ambiguities

  2021cites this paper
• Recent advances in identification of potential drug targets and development of novel drugs in parasitic diseases. Part I: Drug resistance

  2021cites this paper
• Assessment of the Activity of Decoquinate and Its Quinoline-O-Carbamate Derivatives against Toxoplasma gondii In Vitro and in Pregnant Mice Infected with T. gondii Oocysts

  2021cites this paper
• In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.

  2021cites this paper
• Drug Resistance in Protozoal Infections

  2021cites this paper
• Investigation of Antiparasitic Activity of 10 European Tree Bark Extracts on Toxoplasma gondii and Bioguided Identification of Triterpenes in Alnus glutinosa Barks

  2021cites this paper
• Promising Drug Targets and Compounds with Anti-Toxoplasma gondii Activity

  2021cites this paper
• Toxoplasma gondii in South America: a differentiated pattern of spread, population structure and clinical manifestations

  2021cites this paper
• In vivo and in vitro models show unexpected degrees of virulence among Toxoplasma gondii type II and III isolates from sheep

  2021cites this paper
• Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case–control study

  2020cites this paper
• In Vitro and In Vivo Activity of Anogeissus leiocarpa Bark Extract and Isolated Metabolites against Toxoplasma gondii

  2020cites this paper
• Human Toxoplasma infection

  2020cites this paper
• Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis

  2020influential citation
• Copaifera spp. oleoresins impair Toxoplasma gondii infection in both human trophoblastic cells and human placental explants

  2020cites this paper
• Determination of lumefantrine as an effective drug against Toxoplasma gondii infection – in vitro and in vivo study

  2020cites this paper
• Toxoplasmose de la femme enceinte

  2020cites this paper
• Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.

  2019cites this paper
• Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites

  2019cites this paper
• In vitro antitoxoplasmal activity of some medicinal plants

  2019cites this paper
• Therapeutic Targets on Toxoplasma gondii Parasite in Combatting Toxoplasmosis

  2019cites this paper
• ARTESUNATE LOADED NANOFIBER AND ITS COMBINATIONS WITH SPIRAMYCIN FOR TREATMENT OF MURINE TOXOPLASMOSIS

  2019cites this paper
• Treatment of toxoplasmosis: Current options and future perspectives

  2019cites this paper
• Drug Resistance in Protozoan Parasites: An Incessant Wrestle for Survival.

  2019cites this paper
• Treatment of Toxoplasmosis and Neosporosis in Farm Ruminants: State of Knowledge and Future Trends

  2018cites this paper
• Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis.

  2018cites this paper
• Evaluation of current and emerging anti-malarial medicines for inhibition of Toxoplasma gondii growth in vitro

  2018cites this paper
• A new iron(III) complex-containing sulfadiazine inhibits the proliferation and induces cystogenesis of Toxoplasma gondii

  2018cites this paper
• Evaluation of Anti-Toxoplasma gondii Effect of Ursolic Acid as a Novel Toxoplasmosis Inhibitor

  2018cites this paper
• First report of Toxoplasma gondii sporulated oocysts and Giardia duodenalis in commercial green-lipped mussels (Perna canaliculus) in New Zealand

  2018cites this paper
• Novel Toxoplasma gondii inhibitor chemotypes.

  2018cites this paper
• Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.

  2018cites this paper
• Drug Resistance in Toxoplasma gondii

  2018cites this paper
• In vitro activity of the interaction between taxifolin (dihydroquercetin) and pyrimethamine against Toxoplasma gondii

  2018cites this paper
• Antiechinococcal assessment of atovaquone—an in silico and in vitro analysis

  2017cites this paper
• Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box

  2017cites this paper
• Azithromycin treatment is able to control the infection by two genotypes of Toxoplasma gondii in human trophoblast BeWo cells.

  2017cites this paper
• Enrofloxacin and Toltrazuril Are Able to Reduce Toxoplasma gondii Growth in Human BeWo Trophoblastic Cells and Villous Explants from Human Third Trimester Pregnancy

  2017cites this paper
• A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006–2016)

  2017influential citation
• In vitro treatment of Toxoplasma gondii with copper(II) complexes induces apoptosis-like and cellular division alterations.

  2017cites this paper
• Discovery of new inhibitors of Toxoplasma gondii thanks to the Pathogen Box

  2017cites this paper
• Artesunate effect on RH virulent and ME 49 non-virulent strains of Toxoplasma gondii : in vitro and in vivo experimental studies

  2017cites this paper
• Gene mutations in parasitic diseases Part II: Parasite gene mutations

  2017cites this paper
• Synthetic immunostimulatory glycans interference with host cell apoptosis upon of Toxoplasma gondii infection, in vitro

  2017cites this paper
• How Pathogens Survive Drug Pressure

  2017cites this paper
• Mechanisms of Drug Resistance in Toxoplasma gondii

  2017cites this paper
• Synthesis and biological evaluation of anti-Toxoplasma gondii activity of a novel scaffold of thiazolidinone derivatives

  2017cites this paper
• Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil

  2017cites this paper
• Drugs in development for toxoplasmosis: advances, challenges, and current status

  2017influential citation
• Molecular detection and genetic characterization of Toxoplasma gondii in farmed raccoon dogs (Nyctereutes procyonoides) in Shandong province, eastern China.

  2017cites this paper
• Molecular Characterisation of Toxoplasma gondii and Development of Diagnostic Assay for Bradyzoites

  2016cites this paper
• Lectins from Synadenium carinatum (ScLL) and Artocarpus heterophyllus (ArtinM) Are Able to Induce Beneficial Immunomodulatory Effects in a Murine Model for Treatment of Toxoplasma gondii Infection

  2016cites this paper
• Pathogenicity and phenotypic sulfadiazine resistance ofToxoplasma gondii isolates obtained from livestock in northeastern Brazil

  2016cites this paper
• New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections

  2016cites this paper
• The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades: a systematic review.

  2016cites this paper
• Antibacterial properties and mechanisms of gold-silver nanocages.

  2016cites this paper
• Newborn screening for congenital toxoplasmosis in Ireland

  2016cites this paper
• Oxidative stress generated during monensin treatment contributes to altered Toxoplasma gondii mitochondrial function

  2016cites this paper
• Current Therapy of Acquired Ocular Toxoplasmosis: A Review

  2015cites this paper
• Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation

  2015cites this paper
• Effect of 3-Bromopyruvate and Atovaquone on Infection during In Vitro Interaction of Toxoplasma gondii and LLC-MK2 Cells

  2015cites this paper
• Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.

  2015cites this paper
• Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells

  2015influential citation
• Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.

  2015cites this paper
• Reduction of Toxoplasma gondii Development Due to Inhibition of Parasite Antioxidant Enzymes by a Dinuclear Iron(III) Compound

  2015influential citation
• Triazole-Based Compound as a Candidate To Develop Novel Medicines To Treat Toxoplasmosis

  2014cites this paper
• Auranofin Is Highly Efficacious against Toxoplasma gondii In Vitro and in an In Vivo Experimental Model of Acute Toxoplasmosis

  2014influential citation
• Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii.

  2014cites this paper
• 1,4-Disubstituted Thiosemicarbazide Derivatives are Potent Inhibitors of Toxoplasma gondii Proliferation

  2014cites this paper
• [Gene polymorphisms in the dihydrofolate reductase ( dhfr ) and dihydropteroate synthase ( dhps ) genes and structural modelling of the dhps gene in Colombian isolates of Toxoplasma gondii].

  2014cites this paper
• Triazole-based compound as the candidate to develop a novel medicines 1 to treat toxoplasmosis

  2014cites this paper
• Anti-Toxoplasma activity of natural products: a review.

  2014cites this paper
• Polimorfismos en los genes de dihidrofolato-reductasa ( dhfr ) y dihidropteroato-sintasa ( dhps ) y modelado estructural del gen dhps en aislamientos colombianos de Toxoplasma gondii

  2014cites this paper
• Management of Congenital Toxoplasmosis

  2014cites this paper